In this study, we describe the clinical characteristics and molecular profiles of a cohort of patients with YO-CRC, including the distribution of KRAS, BRAF, microsatellite instability (MSI), HER2 amplification, and other alterations. This evidence concerns the gene KRAS and colorectal carcinoma.